

# Sunil Badve

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1850510/publications.pdf>

Version: 2024-02-01

131  
papers

14,811  
citations

66343  
42  
h-index

22832  
112  
g-index

134  
all docs

134  
docs citations

134  
times ranked

16562  
citing authors

#	ARTICLE	IF	CITATIONS
1	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	6.3	31
2	Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 509-516.	2.5	4
3	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	5.2	33
4	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355.	1.6	23
5	Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician's choice for patients with residual triple negative breast cancer. <i>Cancer Research</i> , 2022, 82, PD9-10-PD9-10.	0.9	0
6	Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management. <i>Endocrinology</i> , 2022, 163, .	2.8	5
7	Breast Implant Capsule-Associated Squamous Cell Carcinoma: Report of 2 Patients. <i>International Journal of Surgical Pathology</i> , 2022, 30, 900-907.	0.8	22
8	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	2.4	2
9	Is conservative management of ductal carcinoma in situ risky?. <i>Npj Breast Cancer</i> , 2022, 8, 55.	5.2	6
10	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3235-3241.	7.0	6
11	Protein Profiling of Breast Cancer for Treatment Decision-Making. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 73-81.	3.8	4
12	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	5.5	18
13	Deconvolution of gene expression for microenvironmental cell types in thymomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20623-e20623.	1.6	0
14	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	6.3	62
15	Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases. <i>Cancers</i> , 2021, 13, 315.	3.7	7
16	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. <i>British Journal of Cancer</i> , 2021, 124, 1150-1159.	6.4	11
17	CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 4691.	3.3	53
18	Thymic Carcinomas and Second Malignancies: A Single-Center Review. <i>Cancers</i> , 2021, 13, 2472.	3.7	2

#	ARTICLE	IF	CITATIONS
19	Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. <i>Oncotarget</i> , 2021, 12, 1178-1186.	1.8	6
20	A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. <i>Frontiers in Oncology</i> , 2021, 11, 736620.	2.8	19
21	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	7.3	17
22	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	6.3	319
23	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
24	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367.	7.1	100
25	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2704-2710.	7.0	21
26	ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing. <i>Scientific Reports</i> , 2020, 10, 12123.	3.3	22
27	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	5.2	16
28	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	5.2	90
29	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
30	Tumour-infiltrating lymphocytes in ductal carcinoma <i>in situ</i> (DCIS) – assessment with three different methodologies and correlation with Oncotype DX DCIS Score. <i>Histopathology</i> , 2020, 77, 749-759.	2.9	7
31	AJCC 8 th edition – A step forward. <i>Breast Journal</i> , 2020, 26, 1263-1264.	1.0	2
32	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
33	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.	7.1	161
34	Fibroblastic sarcomas of the mediastinum. <i>Mediastinum</i> , 2020, 4, 26-26.	1.1	0
35	EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 17-26.e8.	2.4	7
36	Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. <i>Breast Cancer Research</i> , 2019, 21, 87.	5.0	26

#	ARTICLE	IF	CITATIONS
37	Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. Breast Cancer Research, 2019, 21, 114.	5.0	17
38	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Journal of Clinical Oncology, 2019, 37, 3484-3492.	1.6	30
39	Ductal carcinoma in situ of breast: update 2019. Pathology, 2019, 51, 563-569.	0.6	43
40	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz051.	2.9	1
41	Splicing factor <i>ESRP1</i> controls <i>ER</i> -positive breast cancer by altering metabolic pathways. EMBO Reports, 2019, 20, .	4.5	48
42	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	27.0	349
43	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology, 2019, 75, 225-235.	2.9	74
44	TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters. Journal of the National Cancer Institute, 2019, 111, 1118-1119.	6.3	8
45	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 867-871.	6.3	41
46	Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues. Scientific Reports, 2019, 9, 5624.	3.3	45
47	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	1.6	505
48	Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. JAMA Oncology, 2019, 5, 1036.	7.1	23
49	EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer. Breast, 2019, 43, 74-80.	2.2	7
50	CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 598-598.	1.6	0
51	ColotypeR gene signature predicts response to cetuximab in colorectal cancer metastases.. Journal of Clinical Oncology, 2019, 37, 599-599.	1.6	0
52	The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 2018, 33, 244-258.e10.	16.8	270
53	Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. Journal of Thoracic Oncology, 2018, 13, 436-446.	1.1	70
54	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 2851-2858.	7.0	65

#	ARTICLE	IF	CITATIONS
55	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	9.6	303
56	Single-cell heterogeneity in ductal carcinoma in situ of breast. <i>Modern Pathology</i> , 2018, 31, 406-417.	5.5	41
57	MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB- <i>NFIB</i> fusion gene. <i>Journal of Pathology</i> , 2018, 244, 143-150.	4.5	74
58	Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. <i>PLoS ONE</i> , 2018, 13, e0204658.	2.5	11
59	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157.	9.6	108
60	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
61	NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12010-12010.	1.6	2
62	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 111-133.	4.3	530
63	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	469
64	The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. <i>Oncotarget</i> , 2017, 8, 108534-108547.	1.8	4
65	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	5.5	230
66	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 3989-4001.	0.9	27
67	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	5.5	68
68	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	5.2	109
69	A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. <i>British Journal of Cancer</i> , 2016, 114, 477-484.	6.4	47
70	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 56.	7.1	183
71	Tumor Heterogeneity in Breast Cancer. <i>Advances in Anatomic Pathology</i> , 2015, 22, 294-302.	4.3	12
72	Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers. <i>Scientific Reports</i> , 2015, 5, 8765.	3.3	55

#	ARTICLE	IF	CITATIONS
73	The Birth of an Adenoid Cystic Carcinoma. International Journal of Surgical Pathology, 2015, 23, 26-27.	0.8	9
74	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Modern Pathology, 2015, 28, 1185-1201.	5.5	205
75	NF- $\kappa$ B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death and Disease, 2015, 6, e1608-e1608.	6.3	48
76	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology, 2015, 26, 1280-1291.	1.2	177
77	An international study to increase concordance in Ki67 scoring. Modern Pathology, 2015, 28, 778-786.	5.5	195
78	Single-cell screening and quantification of transcripts in cancer tissues by second-harmonic generation microscopy. Journal of Biomedical Optics, 2015, 20, 096016.	2.6	5
79	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2015, 373, 2005-2014.	27.0	1,146
80	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. Journal of Clinical Oncology, 2015, 33, 3938-3944.	1.6	223
81	Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. Modern Pathology, 2015, 28, 1415-1427.	5.5	36
82	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Modern Pathology, 2015, 28, 677-685.	5.5	28
83	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology, 2015, 26, 259-271.	1.2	2,122
84	Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146.. Journal of Clinical Oncology, 2015, 33, 1082-1082.	1.6	43
85	Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells. Oncotarget, 2015, 6, 12682-12696.	1.8	52
86	Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. Journal of Cancer, 2014, 5, 633-645.	2.5	9
87	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 2014, 32, 2959-2966.	1.6	1,080
88	Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG1015.. Journal of Clinical Oncology, 2014, 32, 1000-1000.	1.6	23
89	Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146.. Journal of Clinical Oncology, 2014, 32, 1019-1019.	1.6	12
90	INDUCT: A risk score to predict relapse in estrogen-receptorâ€“positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11063-11063.	1.6	1

#	ARTICLE	IF	CITATIONS
91	A proprietary multianalyte test for predicting extreme resistance to neoadjuvant 5-FU based chemoradiation (CTRT) in esophageal adenocarcinoma (EC).. Journal of Clinical Oncology, 2014, 32, 51-51.	1.6	0
92	RNA-sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy compared to matched pretreatment biopsies from the Hoosier Oncology Group trial BRE09-146.. Journal of Clinical Oncology, 2014, 32, 1002-1002.	1.6	0
93	Prognostic ability of CD44 expression in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11062-11062.	1.6	0
94	Prediction of late relapse in patients with estrogen-receptorâ€“positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11065-11065.	1.6	0
95	A proprietary multi-analyte test to predict neoadjuvant treatment response for esophageal and rectal adenocarcinoma patients.. Journal of Clinical Oncology, 2014, 32, 4085-4085.	1.6	0
96	Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130.. Journal of Clinical Oncology, 2014, 32, 7594-7594.	1.6	0
97	Opportunistic infections in a patient with HIV and thymoma. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 413-415.	3.8	1
98	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute, 2013, 105, 701-710.	6.3	442
99	EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor ï¿½. Journal of Clinical Pathology, 2013, 66, 1051-1057.	2.0	13
100	A gene signature to determine metastatic behavior in thymic carcinoma.. Journal of Clinical Oncology, 2013, 31, 7605-7605.	1.6	0
101	FOXA1 Expression in Urothelial Carcinoma of the Renal pelvis. American Journal of Clinical Pathology, 2012, 138, A296.2-A296.	0.7	0
102	Breast-cancer stem cellsâ€“beyond semantics. Lancet Oncology, The, 2012, 13, e43-e48.	10.7	137
103	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. Journal of Clinical Oncology, 2012, 30, 1005-1005.	1.6	28
104	10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.. Journal of Clinical Oncology, 2012, 30, 1021-1021.	1.6	5
105	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2012, 30, 505-505.	1.6	7
106	Next-generation sequencing of thymic malignancies.. Journal of Clinical Oncology, 2012, 30, 7032-7032.	1.6	1
107	Molecular Analysis of Thymoma. PLoS ONE, 2012, 7, e42669.	2.5	37
108	Factors affecting survival of patients with Masaoka stage IV thymic epithelial tumors (TET).. Journal of Clinical Oncology, 2012, 30, 7107-7107.	1.6	0



#	ARTICLE	IF	CITATIONS
109	In silico identification of an epithelial core signature in human tumors.. Journal of Clinical Oncology, 2012, 30, 10628-10628.	1.6	0
110	Factors influencing outcome in thymic epithelial tumors (TET).. Journal of Clinical Oncology, 2012, 30, 7108-7108.	1.6	0
111	A 19-gene prognostic GEP signature (DecisionDx-Thymoma) to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 7106-7106.	1.6	1
112	A 19-gene prognostic GEP signature to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 68-68.	1.6	0
113	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology, 2011, 24, 157-167.	5.5	545
114	Biomarkers for breast cancer stem cells: the challenges ahead. Biomarkers in Medicine, 2011, 5, 661-671.	1.4	17
115	Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 375-384.	2.5	37
116	Promise of computational systems biology for cancer clinical trials: the voyage to be realized?. Personalized Medicine, 2010, 7, 129-131.	1.5	2
117	Differential subcellular expression of protein kinase C beta11 in breast cancer: correlation with breast cancer subtypes. Breast Cancer Research and Treatment, 2010, 124, 327-335.	2.5	16
118	Does Tumor Size Trump Biology?. Clinical Breast Cancer, 2010, 10, 111-112.	2.4	3
119	Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. American Journal of Pathology, 2010, 176, 2139-2149.	3.8	40
120	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 907-922.	2.5	697
121	Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. Journal of Clinical Pathology, 2009, 62, 6-12.	2.0	74
122	Equivalency of RT-PCR and immunohistochemistry: fact or factoid. Breast Cancer Research and Treatment, 2009, 116, 145-147.	2.5	3
123	Correlation of FOXA1 expression with Oncotype Dx recurrence scores. Journal of Clinical Oncology, 2009, 27, 11058-11058.	1.6	0
124	FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival. Clinical Cancer Research, 2007, 13, 4415-4421.	7.0	220
125	Ductal lavage and its histopathologic basis: A cautionary tale. Diagnostic Cytopathology, 2004, 30, 166-171.	1.0	13
126	Small Cells in Hepatoblastoma Lack “Oval” Cell Phenotype. Modern Pathology, 2003, 16, 930-936.	5.5	28



#	ARTICLE	IF	CITATIONS
127	Expression of Invariant Chain (CD 74) and Major Histocompatibility Complex (MHC) Class II Antigens in the Human Fetus1. Journal of Histochemistry and Cytochemistry, 2002, 50, 473-482.	2.5	25
128	D-Dimer Measurements Unhelpful for Ruling In DIC. Laboratory Medicine, 2000, 31, 383-386.	1.2	0
129	Histologic Distribution and Biochemical Properties of Î± <sub>1</sub> -Microglobulin in Human Placenta. American Journal of Reproductive Immunology, 1999, 41, 52-60.	1.2	25
130	Malignant Brenner Tumor Mimicking a Primary Squamous Cell Carcinoma of the Cervix. Gynecologic Oncology, 1999, 74, 487-490.	1.4	2
131	Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. Human Pathology, 1998, 29, 915-923.	2.0	81